SPRUCE BIOSCIENCES INC (SPRB) Fundamental Analysis & Valuation

NASDAQ:SPRB • US85209E2081

Current stock price

63.04 USD
-6.07 (-8.78%)
Last:

This SPRB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SPRB Profitability Analysis

1.1 Basic Checks

  • In the past year SPRB has reported negative net income.
  • In the past year SPRB has reported a negative cash flow from operations.
  • In the past 5 years SPRB always reported negative net income.
  • In the past 5 years SPRB always reported negative operating cash flow.
SPRB Yearly Net Income VS EBIT VS OCF VS FCFSPRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M -50M

1.2 Ratios

  • SPRB's Return On Assets of -73.49% is on the low side compared to the rest of the industry. SPRB is outperformed by 65.32% of its industry peers.
  • SPRB has a Return On Equity of -91.65%. This is comparable to the rest of the industry: SPRB outperforms 47.01% of its industry peers.
Industry RankSector Rank
ROA -73.49%
ROE -91.65%
ROIC N/A
ROA(3y)-78.97%
ROA(5y)-64.86%
ROE(3y)-112.77%
ROE(5y)-88.74%
ROIC(3y)N/A
ROIC(5y)N/A
SPRB Yearly ROA, ROE, ROICSPRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SPRB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRB Yearly Profit, Operating, Gross MarginsSPRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. SPRB Health Analysis

2.1 Basic Checks

  • SPRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SPRB has been increased compared to 1 year ago.
  • Compared to 5 years ago, SPRB has more shares outstanding
  • There is no outstanding debt for SPRB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SPRB Yearly Shares OutstandingSPRB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 200K 400K 600K 800K 1M
SPRB Yearly Total Debt VS Total AssetsSPRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • SPRB has an Altman-Z score of -4.03. This is a bad value and indicates that SPRB is not financially healthy and even has some risk of bankruptcy.
  • SPRB's Altman-Z score of -4.03 is in line compared to the rest of the industry. SPRB outperforms 44.32% of its industry peers.
  • There is no outstanding debt for SPRB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.03
ROIC/WACCN/A
WACC9.41%
SPRB Yearly LT Debt VS Equity VS FCFSPRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 5.17 indicates that SPRB has no problem at all paying its short term obligations.
  • With a Current ratio value of 5.17, SPRB perfoms like the industry average, outperforming 56.84% of the companies in the same industry.
  • A Quick Ratio of 5.17 indicates that SPRB has no problem at all paying its short term obligations.
  • With a Quick ratio value of 5.17, SPRB perfoms like the industry average, outperforming 58.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.17
Quick Ratio 5.17
SPRB Yearly Current Assets VS Current LiabilitesSPRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. SPRB Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 44.42% over the past year.
  • Looking at the last year, SPRB shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)44.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.61%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • Based on estimates for the next years, SPRB will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.90% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y54.16%
EPS Next 2Y29.71%
EPS Next 3Y25.59%
EPS Next 5Y14.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SPRB Yearly Revenue VS EstimatesSPRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2026 2027 2028 2030 2031 2032 50M 100M
SPRB Yearly EPS VS EstimatesSPRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -100 -200 -300

More info and screens

Find the best growth stocksShow best growing peers

1

4. SPRB Valuation Analysis

4.1 Price/Earnings Ratio

  • SPRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SPRB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SPRB Price Earnings VS Forward Price EarningsSPRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRB Per share dataSPRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SPRB's earnings are expected to grow with 25.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.71%
EPS Next 3Y25.59%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SPRB Dividend Analysis

5.1 Amount

  • SPRB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SPRB Fundamentals: All Metrics, Ratios and Statistics

SPRUCE BIOSCIENCES INC

NASDAQ:SPRB (3/27/2026, 8:00:03 PM)

63.04

-6.07 (-8.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-09
Earnings (Next)05-04
Inst Owners86.75%
Inst Owner Change-74.92%
Ins Owners9.24%
Ins Owner Change0.22%
Market Cap86.36M
Revenue(TTM)N/A
Net Income(TTM)-38.97M
Analysts86
Price Target202.22 (220.78%)
Short Float %12.8%
Short Ratio3.12
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.53%
Min EPS beat(2)-38.48%
Max EPS beat(2)-2.58%
EPS beat(4)1
Avg EPS beat(4)-1.3%
Min EPS beat(4)-46.19%
Max EPS beat(4)82.06%
EPS beat(8)4
Avg EPS beat(8)-15.01%
EPS beat(12)7
Avg EPS beat(12)-4.38%
EPS beat(16)10
Avg EPS beat(16)-1.85%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.65%
PT rev (3m)-5.37%
EPS NQ rev (1m)6.25%
EPS NQ rev (3m)-3.87%
EPS NY rev (1m)-5.85%
EPS NY rev (3m)-483.81%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-6.7%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.03
P/tB 2.03
EV/EBITDA N/A
EPS(TTM)-53.36
EYN/A
EPS(NY)-24.46
Fwd EYN/A
FCF(TTM)-24.33
FCFYN/A
OCF(TTM)-24.33
OCFYN/A
SpS0
BVpS31.03
TBVpS31.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -73.49%
ROE -91.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-78.97%
ROA(5y)-64.86%
ROE(3y)-112.77%
ROE(5y)-88.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.17
Quick Ratio 5.17
Altman-Z -4.03
F-Score4
WACC9.41%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.61%
EPS Next Y54.16%
EPS Next 2Y29.71%
EPS Next 3Y25.59%
EPS Next 5Y14.9%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.45%
OCF growth 3YN/A
OCF growth 5YN/A

SPRUCE BIOSCIENCES INC / SPRB Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SPRUCE BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 2 / 10 to SPRB.


Can you provide the valuation status for SPRUCE BIOSCIENCES INC?

ChartMill assigns a valuation rating of 1 / 10 to SPRUCE BIOSCIENCES INC (SPRB). This can be considered as Overvalued.


What is the profitability of SPRB stock?

SPRUCE BIOSCIENCES INC (SPRB) has a profitability rating of 0 / 10.


What is the financial health of SPRUCE BIOSCIENCES INC (SPRB) stock?

The financial health rating of SPRUCE BIOSCIENCES INC (SPRB) is 6 / 10.


What is the earnings growth outlook for SPRUCE BIOSCIENCES INC?

The Earnings per Share (EPS) of SPRUCE BIOSCIENCES INC (SPRB) is expected to grow by 54.16% in the next year.